ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
54 announcements
Cipla Limited has appointed Mr. Vikram Janakiraman as the Global Chief Technical Operating Officer. He joins as Senior Management Personnel with effect from 7th December, 2026.
Cipla delivered record India revenue and margin expansion, masking high-stakes US product approval dependencies.
Cipla granted 8,679 stock options and 27,140 ESARs to employees under its 2013 and 2021 schemes. Exercise price is INR 2 per option with graded vesting.
Cipla's Board appointed Ms. Rashmi Joshi as additional Independent Director for 5 years. This strengthens the board's governance and financial oversight capabilities.
Q2FY27 consolidated revenue INR 7,404 Cr (-2.4% YoY), EBITDA INR 1,388 Cr (18.7% margin), PAT INR 878 Cr (11.9%). Record quarterly India revenue; licensing deals in oncology biosimilars and ADCs.
Cipla reported Q2FY27 consolidated revenue of ₹7,404 Cr and PAT of ₹878 Cr. EBITDA margin expanded 200 bps QoQ to 18.7%, with One-India growing 12% YoY.
Cipla Ltd reported revenue from operations of ₹7,404 Cr (-2.4% YoY) and net profit of ₹851.5 Cr (-37.1% YoY) for Q2 FY27.
Cipla's subsidiary InvaGen received zero Form 483 observations in a routine USFDA cGMP inspection. The clean outcome confirms compliance at its US manufacturing facility.
Cipla Ltd has filed its quarterly shareholding pattern for the quarter ended September 30, 2026, as required under SEBI (LODR) Regulations.
Cipla Ltd will hold a board meeting on October 27, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter.
Cipla allotted 12,168 equity shares following the exercise of options under its ESOS and ESAR schemes. This increases the company's total paid-up share capital.
Cipla Ltd announced that Mr. Venkata Sai Mungara has transitioned to a subsidiary role, ceasing to be a Senior Management Personnel effective October 1, 2026.
Cipla announced it was assigned an ESG rating of 68 by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, a SEBI-registered rating provider.
Cipla is notifying shareholders and creditors about a Scheme of Amalgamation with Inzpera Healthsciences, providing them an opportunity to submit representations to the NCLT.
Cipla signed an exclusive licensing and supply agreement with SBP Group’s CTTQ for the drug Rolditamig Deuderuxtecan. This collaboration aims to accelerate therapy access in licensed markets.
Cipla Ltd. announced an internal restructuring where Aspergen Limited, India, acquired a 100% stake in Aspergen Inc., USA, from existing group subsidiaries.
Cipla allotted 5,281 equity shares to employees upon exercise of options under its ESOS and ESAR schemes.
Cipla reported receiving seven inspectional observations from the USFDA following a cGMP inspection at its Pithampur facility. The company intends to address these observations promptly.
Cipla Ltd announced that the NCLT has allowed the scheme application for the amalgamation of its wholly-owned subsidiary, Inzpera Healthsciences Ltd, into Cipla Ltd.
Cipla Limited received updated ESG ratings from SES and NSE. SES assigned a score of 69.9 while NSE assigned 67 for the FY 2025-26 period.
Cipla announced that its subsidiary, InvaGen, received the Establishment Inspection Report from the USFDA, officially closing the inspection of its Hauppauge facility.
Cipla allotted 7,850 equity shares under its ESOS and ESAR schemes. This allotment increases the company's total issued and paid-up share capital.
Cipla received U.S. FDA approval for its Generic Advair Diskus. The product is expected to launch in the U.S. market in Q2 FY 2026-27.
Cipla delivered record Q1 FY27 revenue of INR 7,119 Cr with 2% reported growth (4% adjusted). Strategy focuses on U.S. respiratory launches and 'One India' chronic therapies.
Cipla Limited granted 5,530 stock options and 19,179 Employee Stock Appreciation Rights. These grants are part of the company's 2013 and 2021 employee incentive schemes.
Cipla has appointed Mr. Dinesh Jain as Global CFO. Mr. Ashish Aduka transitions to an internal business leadership role.
Cipla delivered record Q1 revenue of INR 7,119 Cr, driven by strong growth in India and the US. EBITDA margins stood at 16.7% with PAT at INR 789 Cr.
Cipla reported Q1FY27 revenue of ₹7,119 Crore and PAT of ₹789 Crore. The company achieved its highest-ever quarterly revenue with 12% growth in India.
Cipla Ltd reported revenue from operations of ₹7,119 Cr (+2.3% YoY) and net profit of ₹785.5 Cr (-39.2% YoY) for Q1 FY27.
Cipla Ltd has submitted its shareholding pattern for the quarter ending June 30, 2026. The filing details holdings across promoter and public categories.